Apotex Revenue and Competitors

Weston, FL USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Apotex's estimated annual revenue is currently $1.4B per year.(i)
  • 0

Employee Data

    00

Apotex's People

NameTitleEmail/Phone
1
CEO Apotex Inc.Reveal Email/Phone
2
President & CEOReveal Email/Phone
3
President & CEOReveal Email/Phone
4
CIO ConsultantReveal Email/Phone
5
Chief Corporate Development OfficerReveal Email/Phone
6
Chief Legal OfficerReveal Email/Phone
7
Chief Operations OfficerReveal Email/Phone
8
Chief Financial OfficerReveal Email/Phone
9
Chief StaffReveal Email/Phone
10
Former VP International Sales and MarketingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$32.2M160N/AN/AN/A
#2
$15.1M7523%N/AN/A
#3
$341.9M1701N/AN/AN/A
#4
$16.7M8343%N/AN/A
#5
$10.9M54-4%N/AN/A
#6
$11.3M56-2%N/AN/A
#7
$211.7M12974%N/AN/A
#8
$29.1M1455%N/AN/A
#9
$9.4M47-2%N/AN/A
#10
$11.9M59-8%N/AN/A
Add Company

What Is Apotex?

When it comes to affordable healthcare solutions, you can count on Apotex. One more way we are Advancing Generics.

keywords:N/A

N/A

Total Funding

N/A

Number of Employees

$1.4B

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Apotex News

2022-04-20 - Calcitonin Salmon Market Size, Scope And Forecast | Novartis ...

Novartis, Sanofi, Mylan Pharmaceuticals, Apotex, Upsher-Smith Laboratories, Ferring Pharmaceuticals, Par Pharmaceutical, Torrent,...

2022-04-20 - Clarithromycin Tablets Market Size, Scope And Forecast ...

Abbvie, Abbott, Mylan, Apotex, Sandoz, Takeda Pharmaceuticals, Teva Pharmaceutical, Sun Pharmaceutical, Aurobindo Pharma, Mayne Pharma,...

2022-04-06 - Apotex Corp. Launches Generic of Abraxane® in the United ...

Paclitaxel protein-bound particles for injectable suspension is indicated for the treatment of metastatic breast cancer, non-small cell lung...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$0.1M1-50%N/A
#2
$0.1M2-33%N/A
#3
$0.1M20%N/A
#4
$0.2M3N/AN/A
#5
$0.2M3-25%N/A